文献速递临床生化临床免疫分子诊断

体液生物标志物及其检测技术用于人体肠道通透性评估

Biomarkers in body fluids and their detection techniques for human intestinal permeability assessment.
PubMed 文献 · Clin Chem Lab Med · 2025-08-13

本综述介绍了用于肠道通透性(IP)评估的体液生物标志物,包括糖探针、内毒素、D-乳酸、肠脂肪酸结合蛋白、二胺氧化酶、瓜氨酸、连蛋白和脂多糖结合蛋白,总结了其来源、相关疾病及检测技术。体液标志物检测为IP的无创定量评估提供了有前景的方法,但需更多标志物类型、更准确的生理病理机制及创新传感技术以提升临床可行性。

要点

  • 体液生物标志物可实现肠道通透性的无创定量评估。
  • 糖探针、内毒素、D-乳酸、I-FABP、DAO、瓜氨酸、连蛋白和LBP是主要标志物。
  • 快速、精准、现场化的IP评估有助于肠道及继发性疾病的临床诊断与监测。

核心结论

  • 体液生物标志物检测为肠道通透性的体外评估提供了有前景的方法。
  • 现有研究证明了体液标志物用于IP评估的有效性和可实现性。

研究设计与样本

  • 本文为综述,通过调查现有研究介绍体液中各类IP生物标志物及其检测技术。

主要发现

  • 综述总结了糖探针、内毒素、D-乳酸、肠脂肪酸结合蛋白、二胺氧化酶、瓜氨酸、连蛋白和脂多糖结合蛋白的来源、相关疾病及检测技术。
  • 简要讨论了饮食对肠道生态系统和肠道通透性的调节。

临床怎么用

  • 本综述可作为胃肠病学家、检验技师和研究人员的参考。
  • 体液标志物检测有望用于肠道及继发性疾病的临床诊断和监测。

局限性

  • 需探索更多类型的生物标志物、更准确的生理和病理机制以及更多创新传感技术以提升临床可行性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Intestinal permeability (IP) is a crucial index for intestinal tract integrity, reflecting intestinal barrier function, injury, diseases, and related systemic conditions. However, current mainstream testing methods are invasive and qualitative. Biomarkers for IP in body fluids offer noninvasive and quantitative advantages for IP assessment while pose challenges for high-performance detection techniques. CONTENT: This review introduces the main types of biomarkers for IP, including sugar probes, endotoxin, D-lactic acid, intestinal fatty acid-binding protein, diamine oxidase, citrulline, zonulin and lipopolysaccharide-binding protein. Their sources, associated diseases and detection techniques are summarized, and the regulation of intestinal ecosystem and IP by diet are also briefly discussed. SUMMARY: By investigating existing studies, various biomarkers in body fluids and their detection techniques are introduced, and the effectiveness and realizability of IP assessment with body fluid markers are demonstrated. This review can be as a reference for gastroenterologists, laboratory technicists and researchers. OUTLOOK: Body fluid biomarker detection provides a promising proach for IP in vitro assessment. To improve the feasibility in clinics, more types of biomarkers, more accurate physiological and pathological mechanisms, and more innovative sensing technologies are expected to be explored and developed. It is foreseeable that fast, precise, and on-site IP assessment will contribute to the clinical diagnosis and monitoring of intestinal and secondary diseases.

来源:Clin Chem Lab Med,查看原文。版权归原作者所有。

引用

  1. Zhang J, Wang T, Mao X, et al. Biomarkers in body fluids and their detection techniques for human intestinal permeability assessment. Clin Chem Lab Med. 2025. PMID: 40793775. doi:10.1515/cclm-2025-0318

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。